Stocks and Investing Stocks and Investing
Mon, August 21, 2023
Fri, August 18, 2023

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $11 on, Aug 18th, 2023


Published on 2024-10-28 06:01:23 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $60 to $11 on, Aug 18th, 2023.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 5 other peers that have a rating on BTAI. Out of the 5 peers that are also analyzing BTAI, 3 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $4 on, Tuesday, August 15th, 2023
  • Graig Suvannavejh of "Mizuho" Downgraded from Strong Buy to Hold and Decreased Target to $4 on, Tuesday, August 15th, 2023
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023


These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $31 on, Tuesday, August 15th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, August 15th, 2023

Contributing Sources